Privia Health price target raised to $33 from $31 at Truist

Truist analyst Jailendra Singh raised the firm’s price target on Privia Health (PRVA) to $33 from $31 and keeps a Buy rating on the shares after hosting management talks. The company noted that the sequential decline in FFS Practice Collections was driven by a higher concentration of specialists versus primary care and specific “retroactive” claims processing timing in the California and North Texas markets, also having suggested that averaging Q3 and Q4 results provides a more accurate representation of the underlying performance for the second half of the year, the analyst tells investors in a research note.